ST6GAL1 and cancer: ST6Gal1 marked overexpression in multiple human cancers (including gastric), and the concomitant upregulation of α2,6-sialylation in specific target proteins, have been extensively associated with increased tumor invasive and metastatic capacities, as well as poor patient clinical outcome [10–14].